Low to Intermediate-1 MDS
2 clinical trials · Condition
◉ Watch Low to Intermediate-1 MDS
| Record | Firm | Date |
|---|---|---|
| Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) (NCT01736683) | Merck Sharp & Dohme LLC | 2012-11-28 |
| A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients (NCT00699842) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2008-07-01 |
Track Low to Intermediate-1 MDS automatically
Every clearance here is in the API, with alerts when new ones post.